Over the last several years, the use of radiometals has gained increasing relevance in supporting the continuous development of new, complementary and more specific biological targeting agents. Radiopharmaceuticals labelled with radiometals from elements such as Tc, Zr, Y, Ga and Cu received increasing attention as they find application in both diagnostic SPECT and PET imaging techniques and radiotherapeutic purposes. Such interest stems from the wide variety of radionuclides available with distinct and complementary nuclear decay characteristics to choose from with unequalled specificity, but can also be explained by growing demand in targeted radionuclide therapy. As a result, as routine supply of these radiometals becomes mandatory, studies describing their production processes have expanded rapidly. Although most radiometals are traditionally provided by the irradiation of solid targets in specialized cyclotrons, recently developed techniques for producing radiometals through the irradiation of liquid targets have received growing attention due to compatibility with commonly available small medical cyclotrons, promising characteristics and encouraging results. Irradiating liquid targets to produce radiometals appears as a fast, reliable, convenient and cost-efficient alternative to the conventional solid target techniques, characterized by complex and time-consuming pre- and post-irradiation target handling. Production of radiometals in liquid targets incorporated to complete manufacturing processes for daily routine is already recognized as a viable alternative and complementary supply methodology to existing solid target based infrastructures to satisfy growing clinical demands. For instance, several sites already use the approach to produce 68Ga-radiopharmaceuticals for clinical use. This review article covers the production of common radiometals with clinical potential through the irradiation liquid targets. A comparison with the traditional solid target irradiation methods is presented when relevant.

中文翻译：

---

液态靶中放射性金属的生产。

在过去的几年中，放射性金属的使用在支持不断开发新的，互补的和更具体的生物靶向剂方面越来越重要。Tc，Zr，Y，Ga和Cu等元素的放射性金属标记的放射性药物越来越受到关注，因为它们可用于诊断SPECT和PET成像技术以及放射治疗目的。这种兴趣源自具有无与伦比的特异性可供选择的具有独特和互补核衰变特征的多种放射性核素，但也可以通过对靶向放射性核素治疗的需求增长来解释。结果，由于必须定期提供这些放射性金属，描述其生产过程的研究迅速发展。尽管传统上大多数放射性金属是由专门的回旋加速器中的固体靶材辐照提供的，但由于与常用的小型医用回旋加速器具有相容性，令人鼓舞的特性和令人鼓舞的结果，最近开发的通过液体靶材的辐照生产放射性金属的技术受到越来越多的关注。辐照液态靶以生产放射性金属似乎是常规固态靶技术的一种快速，可靠，方便且具有成本效益的替代方法，其特点是在辐照前和辐照后的靶材处理过程复杂且费时。液体标靶中的放射性金属的生产已被纳入日常的完整制造过程中，已经被认为是现有的基于固体标靶的基础设施的可行替代和补充供应方法，以满足日益增长的临床需求。例如，几个站点已经在使用这种方法来生产68Ga放射性药物用于临床。这篇综述文章涵盖了通过辐照液体靶标生产具有临床潜力的常见放射性金属。相关时，提出了与传统固体靶照射方法的比较。这篇综述文章涵盖了通过辐照液体靶标生产具有临床潜力的常见放射性金属。相关时，提出了与传统固体靶照射方法的比较。这篇综述文章涵盖了通过辐照液体靶标生产具有临床潜力的常见放射性金属。相关时，提出了与传统固体靶照射方法的比较。